MNPR NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Monopar Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 109.9 USD
-1.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 64.0% above the Trend Line and sits at 92.3% of its 52-week range. The latest completed week returned -1.1%, after a 25.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 58/100. Near-term considerations: price is close to its 52-week high; earnings are due in 13d.

Setup score 63 out of 100
Latest Close 109.9 USD 24 Jul 2026
1W Return -1.1% latest completed week
4W Return 25.3% short-term follow-through
12W Return 106.3% quarterly tape
Trend Breadth 51.9% 27 of 52 weeks active
Volume Ratio 1.5x vs 13-week average
What is working
  • The trend backdrop is active with a 4-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 6 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.1% Latest completed week; four-week move 25.3%. Indicator stack 42/91 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 58/100 55 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 64.0% above the Trend Line and sits at 92.3% of its 52-week range. The latest completed week returned -1.1%, after a 25.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.18

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers66 reversal markers

No recent accumulation markers. 6 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 25.3% over four weeks, 106.3% over 12 weeks, and 144.3% over one year. The current trend has remained active for 4 consecutive weeks.

Performance by holding period

1W-1.1%
4W25.3%
12W106.3%
26W46.4%
52W144.3%
Active trend streak4 weeks
Active weeks in one year27
Trend breadth51.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.64Latest activity-pressure read.
Pressure change137.5%Four-week change in activity pressure.
Leadership51.24Latest relative-leadership reading.
RS change115.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality48/100Profitability and accounting quality. Underlying universe rank 53; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-16.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-12.5%
Net share repurchases relative to market value.
Shareholder yield
-12.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity4 / 6

4 acquisitions and 6 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment58/100

Weighted news tone is neutral across 55 relevant articles.

18 positive · 36 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-5.8%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+30.0%Week of 26 Jun.
Worst week-19.5%Week of 30 Jan.
Latest week-1.1%Week of 24 Jul.

Shape of recent returns

Strong gains9
Modest gains6
Flat weeks0
Modest losses5
Sharp losses6
Recent vol10.2%13-week weekly-return volatility.
Base vol11.4%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew10.1% / -6.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape58/100

Trend, activity pressure, participation, and risk combine to a 58/100 tape read.

 Indicator analysis43/100

Latest 12-week confirmation: trend 4/12, activity pressure 10/12, relative leadership 5/12.

Activity pressure 0.50; 6 reversal markers Factors49/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 88; Small Cap Core rank 54 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment58/100

Weighted news tone is neutral across 55 relevant articles.

Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution Insiders4 / 6

4 acquisitions and 6 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 2026109.9 USD-1.1%66.99 USD32.02 USD1.6451.241.3MOn
17 Jul 2026111.1 USD4.2%65.62 USD31.34 USD1.6052.761.3MOn
10 Jul 2026106.6 USD9.0%64.21 USD30.66 USD1.3242.461.1MOn
3 Jul 202697.79 USD11.5%63.14 USD30.00 USD0.9535.07597.5KOn
26 Jun 202687.68 USD30.0%62.56 USD29.40 USD0.6923.831.2MOff
19 Jun 202667.47 USD12.9%62.51 USD28.87 USD0.45-7.89483.7KOff
12 Jun 202659.77 USD0.5%63.31 USD28.46 USD0.48-15.76560.2KOff
5 Jun 202659.48 USD-8.5%63.92 USD28.11 USD0.59-13.91661.9KOff
29 May 202665.04 USD3.0%64.64 USD27.76 USD0.63-9.85573.0KOff
22 May 202663.12 USD6.5%65.34 USD27.37 USD0.26-9.511.1MOff
15 May 202659.27 USD-6.8%65.95 USD27.00 USD-0.16-13.681.2MOff
8 May 202663.58 USD19.4%66.65 USD26.65 USD-0.43-7.49834.1KOff
1 May 202653.25 USD0.1%67.46 USD26.27 USD-0.69-18.12450.0KOff
24 Apr 202653.20 USD-5.4%69.00 USD25.96 USD-0.67-17.15872.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.